MedTrace Logo

A Study of SGN-STNV in Advanced Solid Tumors

NCT04665921 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2025-02-07

No results posted yet for this study

Summary

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors.

The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.

Conditions

  • Carcinoma, Non-Small Cell Lung
  • HER2 Negative Breast Neoplasms
  • Ovarian Neoplasms
  • Uterine Cervical Neoplasms
  • Endometrial Neoplasms
  • Esophageal Neoplasms
  • Gastroesophageal Junction Carcinoma
  • Stomach Neoplasms
  • Colorectal Neoplasms
  • Exocrine Pancreatic Adenocarcinoma
  • Appendiceal Adenocarcinoma
  • Pseudomyxoma Peritonei

Interventions

DRUG

SGN-STNV

Given into the vein (IV; intravenously)

Sponsors & Collaborators

  • Seagen Inc.

    lead INDUSTRY

Principal Investigators

  • Suzanne McGoldrick, MD · Seagen Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-18
Primary Completion
2024-03-01
Completion
2024-03-01
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04665921 on ClinicalTrials.gov